Suppression of the immunoinflammatory cascade by targeting interleukin 6 (IL-6) mediated effects constitutes a therapeutic option for chronic inflammatory diseases. Tocilizumab is the only IL-6 inhibitor (IL-6i) licensed for rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA), but also other agents targeting either IL-6 or its receptor are investigated in various indications.
Schoels, M., Van Der Heijde, D., Breedveld, F., Burmester, G., Dougados, M., Emery, P., Ferraccioli, G., Gabay, C., Gibofsky, A., Gomez Reino, J., Jones, G., Kvien, T., Murakami, M., Murikama, M., Nishimoto, N., Smolen, J., Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement, <<EARD>>, 2013; 72 (4): 583-589. [doi:10.1136/annrheumdis-2012-202470] [http://hdl.handle.net/10807/54001]
Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement
Ferraccioli, Gianfranco;
2013
Abstract
Suppression of the immunoinflammatory cascade by targeting interleukin 6 (IL-6) mediated effects constitutes a therapeutic option for chronic inflammatory diseases. Tocilizumab is the only IL-6 inhibitor (IL-6i) licensed for rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA), but also other agents targeting either IL-6 or its receptor are investigated in various indications.
| File | Dimensione | Formato | |
|---|---|---|---|
|
583.full.pdf
accesso aperto
Tipologia file ?:
Versione Editoriale (PDF)
Licenza:
Creative commons
Dimensione
333.78 kB
Formato
Adobe PDF
|
333.78 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
